Search results for "malattie"

showing 10 items of 1963 documents

Use of ICS/LABA (extra-fine and non-extra-fine) in elderly asthmatics.

2016

Age represents an exclusion criterion in randomized clinical trials designed to test the efficacy and safety of inhaled drugs in asthma. As a consequence, data on efficacy and safety of inhaled corticosteroid (ICS) and long-acting β2 agonist (LABA) combinations in elderly asthmatics are scanty. Older age is associated with an increased proportion of comorbid conditions; in addition, all organ functions undergo a process of senescence, thus reducing their ability to metabolize the agents. Overall, these age-associated conditions may variably, and often unpredictably, affect the metabolism and excretion of respiratory drugs. However, pharmacological treatment of asthma does not follow specifi…

Druglong-acting β2 agonistmedicine.medical_specialtyasthma treatmentmedia_common.quotation_subjectPopulationReviewSettore MED/10 - Malattie Dell'Apparato Respiratorio030204 cardiovascular system & hematologylaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled trialPharmacokineticsInhaled corticosteroidlawmedicinePharmacology (medical)General Pharmacology Toxicology and PharmaceuticseducationAdverse effectIntensive care medicineAsthmamedia_commoneducation.field_of_studyChemical Health and SafetyInhalationbusiness.industryaginglung functionGeneral Medicinemedicine.diseasecomorbidity030228 respiratory systemAnesthesiaPharmacodynamicslong-acting β2 agonistsinhaled corticosteroidsbusinessSafety ResearchTherapeutics and clinical risk management
researchProduct

Human buccal mucosa as an innovative site of drug delivery.

2009

The authors review the ultra-structural aspects and permeability features of normal human oral mucosa, after having recently tested and used it as a new site of systemic drug delivery. The pertinent scientific literature from 1975 through 2009 has been analysed and discussed. Buccal epithelium is a relatively permeable, robust non-keratinized tissue and blood vessels drain directly into the jugular vein; due to its particular features, it has been of increasing interest to researchers as an alternative site of drug administration. The review describes the structure and function of the buccal mucosa, the rationale for transbuccal drug delivery and the main transmucosal drug delivery systems.…

Drugmedia_common.quotation_subjectDentistryAdministration OralPharmacologyBuccal mucosaRoute of administrationDrug Delivery SystemsOral administrationSettore MED/28 - Malattie OdontostomatologicheDrug DiscoverymedicineHumansOral mucosamedia_commonPharmacologybusiness.industryCell MembraneMouth MucosaAdministration BuccalBuccal administrationStructure and functionDrug delivery human oral mucosa transbuccal permeation reconstituted human oral epithelium iontophoresismedicine.anatomical_structurePharmaceutical PreparationsSettore CHIM/09 - Farmaceutico Tecnologico ApplicativoDrug deliverybusinessCurrent pharmaceutical design
researchProduct

Asthma Control: The Right Inhaler for the Right Patient

2015

Inhaled therapy is the cornerstone of asthma management in that it optimizes the delivery of the medication to the site of action. The effectiveness of inhaled therapy is affected by the correct choice of the device and proper inhalation technique. In fact, this influences the drug delivery and distribution along the bronchial tree, including the most peripheral airways. In this context, accumulating evidence supports the contribution of small airways in asthma, and these have become an important target of treatment. In reality, the “ideal inhaler” does not exist, and not all inhalers are the same. Advances in technology has highlighted these differences, and have led to the design of new d…

Drugmedicine.medical_specialtyChemistry Pharmaceuticaldevice asthmamedia_common.quotation_subjectContext (language use)ReviewPeripheral airwaysSettore MED/10 - Malattie Dell'Apparato RespiratorioAsthma managementPatient Education as TopicAsthma controlAsthma controlAdministration InhalationmedicineHumansPharmacology (medical)Intensive care medicineAsthmamedia_commonMedicine(all)Inhalationbusiness.industryNebulizers and VaporizersInhalerInhalerGeneral Medicinemedicine.diseaseAsthmaLung functionAdherenceChronic DiseaseDrug deliveryPatient CompliancebusinessAdvances in Therapy
researchProduct

Inhalation therapy devices for the treatment of obstructive lung diseases: the history of inhalers towards the ideal inhaler.

2020

Inhalation therapy allows conveying drugs directly into the airways. The devices used to administer inhaled drugs play a crucial role in the management of obstructive lung diseases such as asthma and chronic obstructive pulmonary disease (COPD). To ensure high bronchial deposition of the drug, a device should deliver a high proportion of fine particles, be easy to use, and provide constant and accurate doses of the active substance. Nowadays, four different types of inhalers are widely used: nebulizers, dry powder inhalers (DPIs), pressurized metered-dose inhalers (pMDIs), and soft mist inhalers (SMIs). Nebulizers can be used by patients unable to use other inhalers. However, they require l…

Drugmedicine.medical_specialtyRespiratory TherapyRespimatmedia_common.quotation_subjectSettore MED/10 - Malattie Dell'Apparato Respiratorio030204 cardiovascular system & hematologyMDI03 medical and health sciencesRoute of administrationPulmonary Disease Chronic Obstructive0302 clinical medicineAsthma COPD DPI MDI Nebulizer RespimatAdministration InhalationInternal MedicinemedicineCOPDHumans030212 general & internal medicineMetered Dose InhalersIntensive care medicineAsthmamedia_commonCOPDInhalationbusiness.industryInhalerNebulizers and VaporizersNebulizerEquipment Designmedicine.diseaseAsthma; COPD; DPI; MDI; Nebulizer; RespimatAsthmaRespimatDPINebulizerbusinessEuropean journal of internal medicine
researchProduct

Impact of reslizumab on outcomes of severe asthmatic patients: current perspectives.

2018

Approximately 5%-10% of asthmatics suffer from severe asthma. New biological treatments represent a great opportunity to reduce asthma burden and to improve asthma patients' lives. Reslizumab will soon be available in several European countries. This anti-IL-5 IgG4/kappa monoclonal antibody, administered intravenously at a dose of 3 mg/kg over 20-50 minutes every 4 weeks, has been shown to be safe and effective in patients with 400 eosinophils/mu L or more in their peripheral blood. The clinical effects in reducing asthma exacerbations and in improving the quality of life and lung function are clear, but further research is needed to determine the best biological compound for a specific clu…

Drugmedicine.medical_specialtymedia_common.quotation_subjectReview030204 cardiovascular system & hematologySettore MED/10 - Malattie Dell'Apparato Respiratoriopatient-reported outcomeasthma; patient-reported outcomes; personalized medicine; reslizumabPathogenesis030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineReslizumabInternal medicinemedicineAsthmatic patientPathologicalAsthmamedia_commonbusiness.industrypersonalized medicineasthmamedicine.diseasereslizumabpatient-reported outcomesPersonalized medicinebusinessMepolizumabmedicine.drugPatient related outcome measures
researchProduct

Amorphous Ropinirole-Loaded Mucoadhesive Buccal Film: A Potential Patient-Friendly Tool to Improve Drug Pharmacokinetic Profile and Effectiveness

2020

Nowadays the therapeutic strategies to manage Parkinson&rsquo

Drugtherapy optimizationparkinson’s diseasemedia_common.quotation_subjectPeppas-Salhin model.Medicine (miscellaneous)orocomucosal filmslcsh:MedicinePeppas-Salhin model02 engineering and technologyPharmacology030226 pharmacology & pharmacyDosage formArticleorocomucosal film03 medical and health sciencesdissolution kinetic0302 clinical medicinebuccal administrationPharmacokineticsOral administrationSettore MED/28 - Malattie OdontostomatologicheMucoadhesionMedicineEudragit® L100media_commonbusiness.industrylcsh:Rex vivo permeationBuccal administration021001 nanoscience & nanotechnologynervous system diseasesropiniroleRopiniroleSettore CHIM/09 - Farmaceutico Tecnologico Applicativo0210 nano-technologybusinessDrug metabolismdissolution kineticsmucoadhesionmedicine.drug
researchProduct

Increased bronchial epithelial thickness in small airways of mdx mice at rest and after exercise training

2009

Duchenne muscolar dystrophy low intensity endurance training bronchiolar epitheliumSettore MED/10 - Malattie Dell'Apparato RespiratorioSettore BIO/09 - Fisiologia
researchProduct

Bronchial epithelial thickness is increased in small airways of MDX mise at rest and after training

2009

Duchenne muscolar dystrophy low-intensity endurance training bronchiolar epithelium thicknessSettore MED/10 - Malattie Dell'Apparato RespiratorioSettore BIO/09 - Fisiologia
researchProduct

Patients Withdrawing Dupilumab Monotherapy for COVID-19-Related Reasons Showed Similar Disease Course Compared With Patients Continuing Dupilumab The…

2022

N/A

Dupilumab TherapyAntibodies Monoclonal Humanized; Disease Progression; Humans; Treatment Outcome; COVID-19; Dermatitis AtopicDermatitisAtopic dermatitis.DermatologyDupilumabAntibodies Monoclonal HumanizedAntibodiesAtopicDermatitis AtopicSettore MED/35MonoclonalImmunology and AllergyHumanshumanHumanizedAtopic dermatitistreatment outcome Antibodies Monoclonal HumanizedCOVID-19Treatment OutcomeCOVID-19 Dupilumab Therapydisease exacerbationDisease ProgressionSettore MED/35 - MALATTIE CUTANEE E VENEREEHumanmonoclonal antibody atopic dermatiti
researchProduct

Etica e pubblicazione. L’articolo scientifico e l’EBM

2011

EBMSettore MED/30 - Malattie Apparato VisivoPROGETTARE UN ARTICOLO SCIENTIFICOETICA NELLE PUBBLICAZIONI SCIENTIFICHE
researchProduct